The Breast 18 (2009) 204–207

Contents lists available at ScienceDirect

The Breast

journal homepage: www.elsevier.com/brst

Original article

Bone turnover markers in postmenopausal breast cancer treated with fulvestrant – A pilot study

A. Agrawal [a,*], R.A. Hannon [b], K.L. Cheung [a], R. Eastell [b], J.F.R. Robertson [a]

[a] University of Nottingham, Professorial Unit of Surgery, City Hospital Campus, Nottingham University Hospitals, Hucknall Road, Nottingham NG5 1PB, UK
[b] University of Sheffield, Academic Unit of Bone Metabolism, Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Sheffield S5 7AU, UK

ARTICLE INFO

Article history:
Received 21 January 2009
Received in revised form
2 April 2009
Accepted 16 April 2009

Keywords:
Bone markers
Breast cancer
Locally advanced
Fulvestrant
Antiestrogen

ABSTRACT

Background: Tamoxifen has a protective effect on bone metabolism in breast cancer; aromatase inhibitors deleterious and that of fulvestrant is unknown.

Methods: Fourteen locally advanced breast cancers with clinical benefit on fulvestrant (250 mg/month) as first-line primary endocrine therapy had sequential serum bone-specific alkaline phosphatase (BAP), N-terminal propeptide of procollagen type 1 (PINP) and C-terminal telopeptide (CTX) at 0, 1, 6, 12, and 18 months. Mean percentage changes (95% CI) were calculated.

Results: Changes from baseline at 1, 6, 12, and 18 months with BAP (3.9–46.8 ng/ml) were +1.5 (−9.8 to +12.9), +2.2 (−22.1 to +26.6), +17.6 (−12.4 to +47.6), +10.8 (−29.9 to +51.7); with PINP (20.6–82.1 ng/ml) were +3.4 (−12.0 to 19.0), +18.8 (−36.7 to +74.2), +47.5 (−21.4 to 116.3), +33.3 (−49.5 to +116.1) and with CTX (0.14–1.35 ng/ml) were +30.8 (0.1 to +61.6), +13.9 (−22.3 to +50.2), +42.9 (−12.7 to +98.5), +45.2 (−28.3 to +118.8).

Conclusions: Long-term (18 months) stability of bone markers may be exploited by using fulvestrant earlier in sequence of endocrine therapies particularly in adjuvant setting in those with pre-existing decreased bone mass.

Background

The increased bone turnover that accompanies declining estrogen levels at the onset of menopause in women leads to decreased bone mass and increased risk of fracture. In postmenopausal women with breast cancer this may be further aggravated by treatment with antiestrogen. Aromatase inhibitors such as anastrozole (Arimidex™, AstraZeneca), letrozole (Femara™, Novartis) or exemestane (Aromasin™, Pfizer) do not have any estrogenic agonistic activity and cause increased bone turnover resulting in significant loss in bone mass.[1] Tamoxifen, however, affords some protection by virtue of its partial agonistic activity.[2–4]

Fulvestrant (Faslodex™, AstraZeneca) is a new estrogen receptor (ER) antagonist with no estrogen agonist effects[5] and has a novel mode of action; it binds, blocks and increases degradation of ER protein, leading to an inhibition of estrogen signaling through the ER.[6,7] In a prospectively planned combined analysis of the data from two randomized trials of similar design (Trials 20 and 21) fulvestrant was reported to be at least as effective as anastrozole in terms of time to progression (TTP; 5.5 months vs. 4.1 months, respectively).[8] A subsequent prospectively planned, combined analysis of survival data reported that the median overall survival was not significantly different between the two treatments.[9] In a further double-blind, randomized phase III trial (Trial 0025) fulvestrant (250 mg/month) was compared with tamoxifen (20 mg/day) in the first-line treatment of postmenopausal women with advanced breast cancer.[10] Prospective planned analysis of patients with ER and/or progesterone receptor (PgR) positive tumours (~80% of the population) showed median TTP of 8.2 months for fulvestrant and 8.3 months for tamoxifen with similar clinical benefit (CB) and objective response (OR) rates and overall survival between groups. However, to date there has been no data of the effect of fulvestrant on bone metabolism in humans.

Bone is constantly renewed by the process of bone remodelling, in which old bone is resorbed by osteoclasts and replaced by new bone, which is laid down by osteoblasts. Markers of bone resorption

Abbreviations: LAPC, locally advanced primary breast cancer; BAP, bone-specific alkaline phosphatase; PINP, N-terminal propeptide of procollagen type 1; CTX, C-terminal telopeptide; ER, estrogen receptor; TTP, time to progression; PgR, progesterone receptor; CB, clinical benefit; OR, objective response; MBC, metastatic breast cancer; SD, stable disease; CV, coefficient of variation; CIs, confidence intervals.

* Corresponding author. Tel.: +44 115 82 31878/76; fax: +44 115 82 31877.
E-mail addresses: amit.agrawal@nottingham.ac.uk (A. Agrawal), r.a.hannon@sheffield.ac.uk (R.A. Hannon), kl.cheung@nottingham.ac.uk (K.L. Cheung), r.eastell@sheffield.ac.uk (R. Eastell), john.robertson@nottingham.ac.uk (J.F.R. Robertson).

0960-9776/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.breast.2009.04.002

and formation, measured in serum or urine, reflect the activity of osteoclasts and osteoblasts, respectively. This study is the first to report the effect of fulvestrant on markers of bone turnover when used in postmenopausal women with locally advanced primary breast cancer (LAPC) in whom there was no evidence of overt metastatic disease.

Materials and methods

Patients

Postmenopausal women with LAPC or metastatic breast cancer (MBC) received fulvestrant (250 mg) as their first-line primary endocrine therapy (so patients were endocrine naïve) as part of an open-label prospective clinical trial that had received approval of the institutional Ethics Committee. Patients underwent staging investigations as per study protocol and included blood tests (full blood count, liver function tests, calcium, phosphate, CA15.3 and CEA), chest X-ray and pelvic X-ray for potential skeletal metastases. Bone scintigram was used if plain radiography was not definitive in diagnosing or ruling out metastases. Patients gave written informed consent for the trial including sequential serum samples and tissue biopsies. Twenty-five of 30 patients with LAPC/MBC who were recruited in this study had clinical benefit (CB). The remaining 5 patients progressed within 6 months and were not included in the study. Of the 25 patients with CB, 2 males and 4 MBC patients were not included in the analysis. Thus, a series of 19 postmenopausal women with endocrine-naïve LAPC (primary breast cancer >5 cm and/or skin involvement) who had CB during fulvestrant therapy were included. Patients with CB were selected so that any bone marker changes would reflect likely the activity of fulvestrant on bony tissue and not disease progression including bone metastasis (and so the MBC patients were excluded).

Patients with LAPC had tumours of TNM stage IIb, IIIa or IIIb (Table 1). Fulvestrant (250 mg) was administered as a once-monthly intramuscular injection into the gluteus muscle. Patients had regular 3 monthly clinical examinations along with CA15.3 and CEA assessments. CB was defined as objective response (complete or partial response) or stable disease [SD] for $\geq$6 months' duration.[11,12]

Bone marker assessments

Sequential blood samples were taken at baseline and after 1, 6, 12 and 18 months of fulvestrant treatment with majority of patients still being on treatment at 18 months. Patients were not strictly fasting though the large majority of samples were taken at the same time of the day (late mornings).

The clotted blood samples were centrifuged (1000 g for 15 min), and the serum suitably aliquoted and stored at $-20\,^{\circ}$C. All samples taken from the same patient were analyzed in the same batch at the end of the study. Serum was analyzed for the following markers of bone formation and resorption.

The bone formation markers, bone alkaline phosphatase (BAP) and N-terminal propeptide of procollagen type 1 (PINP), and the bone resorption markers were measured. Bone ALP, an isoenzyme of alkaline phosphatase, was measured using an automated chemiluminescent immunoenzymatic assay (Beckman Access Ostase™ 37300). Intra-assay coefficient of variation (CV) was $<$2.6% and the normal reference range for postmenopausal women was 3.9–46.8 ng/ml. PINP, a by-product of type I collagen synthesis, was measured by a quantitative radioimmunoassay (Orion Diagnostica UniQ™ PINP RIA). The intra-assay CV was 6.0% and the normal reference range for postmenopausal women was 20.6–82.1 ng/ml.

Serum CTX, a degradation product of crosslinked type I collagen, was measured by an enzyme-linked immunoassay (Serum Crosslaps™, Nordic Bioscience Diagnostics). The intra-assay CV was 3.9% and the normal reference range for postmenopausal women was 0.14–1.35 ng/ml.

Statistical analysis

Data were analyzed using Statgraphics Plus™ version 5 (Herndon, VA) statistical software. Data are presented as mean percentage change (from baseline) in marker level with 95% confidence intervals (CIs).

Table 1
Patient and disease baseline characteristics.

	LAPC ($n=19$)
Median age, years (range)	73.6 (54.9–90.9)
Tumour grade, *n* (%)	
1	4 (21.1)
2	13 (68.4)
3	2 (10.5)
Estrogen receptor (ER) status	
Median ER H-score	220
% Cells staining positive	100

Results

The patient and disease characteristics are shown in Table 1. The median duration of CB for patients receiving fulvestrant was 28.0+ months (range: 10.9–55.4 months; treatment ongoing in 15 patients at 18 months and in 11 patients at the time of analysis).

There were no 'baseline' data for 5 patients in whom a sample of blood at baseline was not available. Therefore, 14 patients had bone marker measurements at baseline, 1, 6, 12 and 18 months. Mean percentage change (from baseline) in serum PINP, bone ALP and CTX levels in these 14 patients is shown in Table 2. Wilcoxon signed rank test did not show any significant difference from baseline at any time-point for any of the 3 markers in these patients.

Of the 5 patients who did not have baseline sample available, the marker assessment was over a 17-month period from 1 to 18 months. Kruskal–Wallis analysis revealed no significant changes in bone markers between any of the time-points over this 17-month period in these patients. Similarly, in all 19 patients with LAPC, no significant changes were apparent over the 18-month period.

Discussion

LAPC patients who had shown CB were selected for this study so that bone turnover marker levels being estimated were not confounded by the presence of overt or occult progressive bony metastases. Furthermore since median time to progression of disease was about 24 months, only samples collected in the first 18 months of the trial were used for marker assessments. This was to avoid as far as possible confounding the results with any early biochemical evidence due to undiagnosed progression of occult bony metastases or the development of new overt bony metastases.

The chosen bone formation and resorption markers are established markers of bone turnover which have been validated in several studies.[13] Although bone markers have high intra-individual variability and diurnal variation (especially CTX)[14] they provide more dynamic and earlier measurement of the skeletal status when compared with bone mineral density measurement.[15,16] Serum markers, however, exhibit less intra-individual variation than urinary markers.[13]